Search
Our Supporters
Members' area
Please enter your password and login or 'click here to register'
Sign up for our email broadcasts
You are here: Product News » Product News » Sandoz expands CV portfolio
Sandoz expands CV portfolio
Teva launches rivastigmine
By Ailsa Colquhoun
26th of June 2012
Sandoz is to market several new formulations for cardiovascular health.
Candesartan: Candesartan Cilexetil tablets are indicated for essential hypertension in adults and as add on/alternative therapy to ACE inhibitors in adult patients with heart failure and impaired left ventricle systolic function. The licensed presentations are 4mg, 8mg, 16mg and 32mg.
Moxonidine: Indicated for mild to moderate essential hypertension are: 200mcg, 300mcg and 400mcg
Sandoz is also marketing Quetiapine, Atorvastatin and Ibandronic acid
Teva rivastigmine: Teva has launched rivastigmine, indicated in the symptomatic treatment of mild to moderately severe Alzheimer's dementia, and in the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
28-tablet packs are available in 1.5mg, 3mg, 4.5mg and 6mg strengths, priced at: £18.29, and 56-tablet packs at £36.58 (initial retail price). The current reimbursement price for all strengths is £33.25, there is as yet no DT price for 56 pack size.
Discontinued
By sanofi-aventis:
- Metenix 5mg tablets (metolazone)
- Skelid 200mg Tablet (disodium tiludronate)
- Surmontil 10mg and 25mg tablets (trimipramine maleate)
- Lantus OptiSet 100 units/ml solution for injection in a pre-filled pen (insulin glargine)